drugset / Trial / NCT00002327

The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

NCT00002327

Phase 1 Completed 40 enrolled Gilead Sciences
Treatment

Summary

To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection. To investigate whether topical HPMPC therapy can induce regression of condyloma acuminatum in patients with HIV infection.

Timeline

Start
Primary completion
Completion

Publications

  • Background Douglas J, Corey L, Tyring S, Kriesel J, Bowden B, Crosby D, Berger T, Conant M, McGuire B, Jaffe HS. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:126 (abstract no 334)

Drugs

EvaluationDrugModalityDoseRoute
Subject CIDOFOVIR ANHYDROUS Small molecule 0.3 % Topical
Subject CIDOFOVIR ANHYDROUS Small molecule 1 % Topical